Key result
Post-mRNA vaccine myocarditis remains rare with very low mortality despite ongoing diagnostic challenges.
Why the study?
The diagnosis of acute myocarditis following SARS-CoV-2 mRNA vaccination remains challenging despite its rarity and low mortality, with incidence varying by vaccine type, sex, age, and dose number.
The review highlights the clinical and diagnostic elements necessary to suspect and diagnose acute myocarditis as a rare adverse event of SARS-CoV-2 mRNA vaccination.
Answers are grounded in this paper and cite their sources.
Myocarditis after mRNA vaccination remains rare with low mortality; leaves open refined diagnostic approaches and risk stratification by age, sex, and dose.
The occurrence of acute myocarditis following the administration of mRNA vaccines against SARS-CoV-2 remains relatively rare, and it is associated with a very low mortality rate. The incidence varied by vaccine type, sex, and age and after the first, second, or third vaccination dose. However, the diagnosis of this condition often remains challenging. To further elucidate the relationship between myocarditis and SARS-CoV-2 mRNA vaccines, starting with two cases observed at the Cardiology Unit of the West Vicenza General Hospital located in the Veneto Region, which was among the first Italian areas hit by the COVID-19 pandemic, we performed a review of the available literature to highlight the clinical and diagnostic elements that could contribute to suspicion of myocarditis as an adverse event of SARS-CoV-2 immunization.
No takes yet. Share an insight, caveat, or question.
Zuin et al. (2023) conducted a review in Acute myocarditis. SARS-CoV-2 mRNA vaccines was evaluated. Acute myocarditis following SARS-CoV-2 mRNA vaccination is a rare adverse event with very low mortality, though its diagnosis remains challenging based on a review of available literature.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: